Impacto da Combinação de Terapêutica Farmacológica na Mortalidade em Doentes com Síndrome Coronária Aguda

INTRODUCTION: Conventional risk stratification after acute myocardial infarction is usually based on the extent of myocardial damage and its clinical consequences. However, nowadays, more aggressive therapeutic strategies are used, both pharmacological and invasive, with the aim of changing the course of the disease. OBJECTIVES: To evaluate whether the number of drugs administered can influence survival of these patients, based on recent clinical trials that demonstrated the benefit of each drug for survival after acute coronary events. METHODS: This was a retrospective analysis of 368 consecutive patients admitted to our ICU during 2002 for acute coronary syndrome. A score from 1 to 4 was attributed to each patient according to the number of secondary prevention drugs administered--antiplatelets, beta blockers, angiotensin-converting enzyme inhibitors and statins--independently of the type of association. We evaluated mortality at 30-day follow-up. RESULTS: Mean age was 65 +/- 13 years, 68% were male, and 43% had ST-segment elevation acute myocardial infarction. Thirty-day mortality for score 1 to 4 was 36.8%, 15.6%, 7.8% and 2.5% respectively (p < 0.001). The use of only one or two drugs resulted in a significant increase in the risk of death at 30 days (OR 4.10, 95% CI 1.69-9.93, p = 0.002), when corrected for other variables. There was a 77% risk reduction associated with the use of three or four vs. one or two drugs. The other independent predictors of death were diabetes, Killip class on admission and renal insufficiency. CONCLUSIONS: The use of a greater number of secondary prevention drugs in patients with acute coronary syndromes was associated with improved survival. A score of 4 was a powerful predictor of mortality at 30-day follow-up

Variáveis Ecocardiográficas Predizentes de Terapêuticas Apropriadas de Taquidisritmias Ventriculares em Doentes Submetidos a Terapêutica de Ressincronização Cardíaca Combinada

INTRODUCTION: The significant risk of sudden arrhythmic death in patients with congestive heart failure and electromechanical ventricular dyssynchrony has led to increased use of combined cardiac resynchronization therapy defibrillator (CRT-D) devices. OBJECTIVES: To evaluate the echocardiographic variables in patients undergoing CRT-D that predict the occurrence of appropriate therapies (AT) for ventricular tachyarrhythmia. METHODS: We analyzed 38 consecutive patients (mean age 60 +/- 12 years, 63% male) with echocardiographic evaluation before and 6 months after CRT-D implantation. Patients with AT were identified in a mean follow-up of 471 +/- 323 days. A standard echocardiographic study was performed including tissue Doppler imaging (TDI). Responders were defined as patients with improvement in NYHA class of < or = 1 in the first six months, and reverse remodeling as a decrease in left ventricular end-systolic volume of < or = 15% and/or an increase in left ventricular ejection fraction of > 25%. RESULTS: The responder rate was 74%, and the reverse remodeling rate was 55%. AT occurred in 21% of patients, who presented with greater left ventricular end-diastolic internal diameter (LVEDD) before implantation (86 +/- 8 vs. 76 +/- 11 mm, p = 0.03) and at 6 months (81 +/- 8 vs. 72 +/- 14 mm, p = 0.08), and increased left ventricular end-systolic internal diameter (66 +/- 14 vs. 56 +/- 14 mm, p = 0.03) and lower ejection fraction (24 +/- 6 vs. 34 +/- 14%, p = 0.08) at 6 months. In the group with AT, the responder rate was lower (38 vs. 83%, p = 0.03), without significant differences in reverse remodeling (38% for the AT group vs. 60%, p = 0.426) or in the other variables. By univariate analysis, predictors of AT were LVEDD before implantation and E' after implantation. Age, gender, ischemic etiology, use of antiarrhythmic drugs, reverse remodeling and the other echocardiographic parameters did not predict AT. In multivariate logistic regression analysis, both LVEDD before implantation (OR 1.24, 95% CI 1.04-1.48, p = 0.019) and postimplantation E' (OR 0.27, 95% CI 0.09-0.76, p = 0.014) remained as independent predictors of AT. CONCLUSIONS: In patients undergoing CRT-D, episodes of ventricular tachyarrhythmia occur with high incidence, independently of echocardiographic response, with LVEDD before implantation and E' after implantation as the only independent predictors of AT in the medium-term. These results highlight the importance of combined devices with defibrillation capability.

Aneurismas das Artérias Viscerais: Alternativa Terapêutica

The authors report two cases in which stent grafts were used to treat visceral artery aneurysms. Case number 1 was a 42-year old woman with a history of renal colic who was found to have a right renal artery aneurysm. Two 6-mm x 20-mm Wallgraft endoprosthesis (Boston Scientific, Watertown, Mass) were placed across the aneurysm neck. Case number 2 was a 72 year-old woman with a past medical history significant for hepatic angioma and hypothyroidism. She was found to have a superior mesenteric artery aneurysm that was treated with a 6-mm x 17-mm Jostent stent graft (Jomed, GmbH, Ra). In both cases the aneurysm was completely excluded and distal end-organ flow preserved. Stent graft placement is a safe and effective treatment for visceral artery aneurysms. If this approach proves durable and reproducible, it can become the method of choice for the management of visceral artery aneurysms in selected patients.

Úlceras Esofágicas Idiopáticas em Mulher VIH+: Terapêutica com Talidomida

Apresenta-se o caso clínico de uma doente seropositiva para o vírus da imunodeficiência humana (VIH+) com um quadro de esofagite idiopática com excelente resposta à terapêutica com talidomida, associando-se regressão do síndrome febril que se manifestara concomitantemente. O mecanismo de acção da talidomida nestes casos é desconhecido, mas poderá estar relacionado com os efeitos do fármaco sobre o sistema imunitário ou dever-se a um efeito anti-retroviral directo.

Trombose Muito Tardia de Stent Coronário Após Suspensão de Terapêutica Antiagregante Plaquetária

Percutaneous transluminal coronary angioplasty (PTCA) with stent placement is widely used to achieve myocardial revascularization in patients with symptomatic ischemic heart disease and significant coronary artery stenosis. Drug-eluting stents are used in most patients undergoing percutaneous angioplasty. Stent thrombosis is an uncommon but serious complication, manifested mostly by sudden death or acute ST-elevation myocardial infarction. The authors report the case of a 68-year-old patient with acute anterior ST-elevation myocardial infarction. Five years previously, she had had a similar presentation and underwent primary angioplasty of the left anterior descending artery with implantation of a drug-eluting stent. The patient was discharged under antithrombotic therapy. She discontinued antiplatelet therapy and two days later suffered an acute anterior myocardial infarction. Primary angioplasty revealed stent thrombosis.

Benefícios da Terapêutica de Ressincronização Cardíaca na «Miocardiopatia Muito Dilatada»

INTRODUCTION: Recent clinical trials have studied parameters that could predict response to cardiac resynchronization therapy (CRT) in patients with advanced heart failure. Left ventricular end-diastolic dimension (LVEDD) is regarded as a possible predictor of response to CRT. OBJECTIVE: To study the response to CRT in patients with very dilated cardiomyopathy, i.e. those at a more advanced stage of the pathology, analyzing both the responder rate and reverse remodeling in two groups of patients classified according to LVEDD. METHODS: We performed a retrospective analysis of 71 patients who underwent CRT (aged 62 +/- 11 years; 65% male; 93% in NYHA functional class > or = III; 31% with ischemic cardiomyopathy; left ventricular ejection fraction [LVEF] 25.6 +/- 6.8%; 32% in atrial fibrillation; QRS 176 +/- 31 ms). Twenty-two (31%) patients with LVEDD > or = 45 mm/m2 (49.2 +/- 3.5 mm/m2) were considered to have very dilated cardiomyopathy (Group A) and 49 patients had LVEDD > 37 mm/m2 and < 45 mm/m2 (39.4 +/- 3.8 mm/m2) (Group B). All patients were assessed by two-dimensional echocardiography at baseline and six months after CRT. The following parameters were analyzed: NYHA functional class, LVEF and LVEDD. Responders were defined clinically (improvement of > or = 1 NYHA class) and by echocardiography, with a minimum 15% increase over baseline LVEF combined with a reduction in LVEDD (reverse remodeling). RESULTS: There were no significant differences in baseline demographic characteristics between the two groups. At six-month followup, we observed an improvement in LVEF (delta 8.5 +/- 11.8%) and a reduction in LVEDD (delta 3.7 +/- 6.8 mm/m2), with fifty-seven (79%) patients being classified as clinical responders. The percentage of patients with reverse remodeling was similar in both groups (64% vs. 73%, p = NS), as were percentages of improved LVEF (delta 6.3 +/- 11% vs. delta 9.6 +/- 12%; p = NS) and decreased LVEDD (delta 3.7 +/- 5.5 mm/m2 vs. delta 3.7 +/- 7.4 mm/m2; p = NS). We found a higher percentage of clinical responders in patients with very dilated cardiomyopathy (96% vs. 72%, p < 0.05). CONCLUSION: In this study, a significant number of responders showed reverse remodeling after CRT. Although a higher percentage of patients with very dilated cardiomyopathy showed improvement in functional class, the extent of reverse remodeling was similar in both groups.

Avaliação dos Custos da Consulta de Medicina/Imunodeficiência em 2002

O consumo de recursos económicos com a Saúde é uma preocupação constante dos governantes, dos administradores hospitalares e também dos profissionais de Saúde, sendo a área do seguimento/tratamento dos doentes infectados pelo Vírus da Imunodeficiência Humana (VIH) apontada como uma das que mais recursos consome. Os AA procuraram, pela avaliação dos doentes seguidos na Consulta de Medicina/Imunodeficiência do Hospital de Santo António dos Capuchos durante o período de um ano (2002), aferir de forma concreta os custos de funcionamento da mesma. Material e Métodos: Foram avaliados os utentes da Consulta de Medicina/Imunodeficiência do Hospital de Santo António dos Capuchos (HSAC) que nela compareceram, pelo menos, duas vezes durante o ano de 2002. O cálculo dos custos das consultas e dos exames complementares de diagnóstico baseou-se nos valores definidos nos Grupos de Diagnósticos Homogéneos (GDHs). O custo da terapêutica anti-retroviral foi calculado segundo os valores que nos foram fornecidos pela Farmácia do Hospital e assumindo o fornecimento mensal da mesma. Resultados: Foram avaliados 107 doentes correspondendo a 498 consultas (€11.424). Fizeram-se 244 determinações de carga viral €(24.321) e 245 estudos de subpopulações linfocitárias (€15.445). As restantes análises custaram €36.586. Dos 107 doentes, 85 estavam sob terapêutica anti-retroviral, com 3 ou 4 fármacos, tendo sido gasto, em média e por doente, €7.122. Foi necessário o internamento de 18 doentes, num total de 219 dias (€41.699). Conclusão: O custo médio anual por doente foi de €6.408.

Infecção pelo Vírus da Hepatite B em Doentes Sujeitos a Terapêutica Imunossupressora ou Quimioterapia Citotóxica. A Propósito de um Caso Clínico

A reactivação do vírus da hepatite B em doentes com neoplasias hematológicas é uma complicação frequente da quimioterapia ou da terapêutica imunomoduladora. Os autores descrevem o caso dum doente com linfoma não-Hodgkin e história de infecção passada pelo VHB que desenvolveu hepatite fulminante após quimioterapia. Os mecanismos de reactivação do VHB são discutidos e as recomendações sobre profilaxia são apresentadas.

Terapêutica Trombolítica no Enfarte Agudo do Miocárdio: Motivos de Inelegibilidade

STUDY OBJECTIVE: to establish the reasons of ineligibility for thrombolytic therapy (TL) in a group of patients with acute myocardial infarction (AMI). DESIGN: retrospective analysis of protocols and clinical records. SETTING: the medical intensive care unit (ICU) of a tertiary care hospital. PATIENTS AND METHODS: we studied the records from patients with AMI admitted to the ICU during a five-year period (1987-91) and excluded from TL, to determine the cause(s) of ineligibility. RESULTS: we found 1669 patients with AMI, 89 of which were excluded from the study. Of the remaining 1580 patients, 1274 (80.6%) did not receive TL. Mean age was 64.4 years; 66.4% were men. Mortality was 24.6%. Mean duration of chest pain was 19.4 hours. Chief reasons for exclusion from TL were advanced age (43.1% of patients) and delayed presentation (55.7%); one of these was present in 79.2%. CONCLUSIONS: this study confirmed the high mortality of patients with AMI who do not receive TL. Advanced age and delayed presentation were the main causes of ineligibility. As age is being abandoned as an exclusion criterion, efforts for expansion of TL should center on the earlier arrival of patients to centers where it is available.

Fístulas Carótido-Cavernosas. Perspectivas de Diagnóstico e Terapêutica

Even though in clinical practice carotid cavernous fistulas (CCF) are not a frequent pathology, it should be a diagnostic hypothesis in face of a suggestive clinical presentation. We intended to review the diagnosis and the therapeutics, comparing them with the actual perspectives. Files of 25 patients with the diagnostic hypothesis of CCF, confirmed by conventional angiography in the HSAC Neuroradiology Department, were reviewed. In this group of patients, (5 males and 20 females), the fistulous aetiology was spontaneous in 10 and traumatic in 15. Clinically the symptom most often presented was diplopia (23 cases) and the most frequent encountered sign was ophthalmoplegia (20 cases). Of the Neuroradiologic investigation, CT scan (done to all patients) have shown an prominent superior ophthalmic vein as the most frequent abnormality. Angiographic study was based on Lasjaunias et al protocol (Surgical Neuroangiography, Vol. 2, Springer-Verlag). Surgery was the therapeutic approach for the traumatic fistulas; only 2 of the spontaneous were treated by endovascular route. Three patients are still under observation. In all the others cases there was a fistula exclusion.

Terapêutica Anti-Retroviral na Infecção a VIH (1ª Parte)

Faz-se uma breve revisão sobre a imunofisiopatologia da infecção pelo VIH. Abordam-se os fármacos que se encontram em investigação clínica mais avançada e alguns que poderão ter interesse futuro. Destacam-se os compostos actualmente disponíveis para uso clínico, tentando abordar os aspectos que na prática clínica são mais importantes. Referenciam-se ensaios clínicos quanto à eficácia nestas drogas em monoterapia ou combinação.

Bombas de Efluxo em Pseudomonas Aeruginosa. Importância Clínica na Terapêutica

As infecções severas causadas por Pseudomonas Aeruginosa têm assumido na última década um papel de destaque, dado tratar-se de um microrganismo de difícil erradicação e com elevada resistência intrínseca e adquirida. Em P. aeruginosa foram caracterizados sete sistemas de bombas de efluxo, os quais contribuem para o desenvolvimento de fenótipos de multiresistência às classes de antibióticos clinicamente mais relevantes. Dado que a terapêutica seleccionada pode actuar como indutora e originar eventos mutacionais que promovem a hiperexpressão das bombas de efluxo, o tratamento destas infecções constitui um grande desafio terapêutico e impõe um conhecimento actualizado desta temática. Esta revisão foi assim desenvolvida com o intuito de rever a contribuição da hiperexpressão dos sistemas de bombas de efluxo em P.aeruginosa, na multirresistência aos antibióticos. Pretendeu-se também avaliar a possibilidade da utilização destes sistemas como alvos terapêuticos de modo a restabelecer a susceptibilidade aos antibióticos disponíveis.

O Comité das regiões da União Europeia : a persistência dos seus poderes consultivos

Dissertação apresentada para cumprimento dos requisitos necessários à obtenção do grau de Mestre em Ciência Política e Relações Internacionais, especialização em Estudos Europeus

Incidência de Arritmias Ventriculares em Doentes com Disfunção Sistólica Ventricular Esquerda Grave: Existe Benefício Após Terapêutica de Ressincronização Cardíaca

Introdução: A terapêutica de ressincronização cardíaca (TRC) tem benefícios significativos em doentes seleccionados. O impacto desta modalidade na incidência de taquidisritmias ventriculares permanece controverso. Analisámos a ocorrência de terapêuticas apropriadas em doentes submetidos a TRC combinada com cardioversor-desfibrilhador (CDI). Métodos: Estudo de 123 doentes com fracção de ejecção ventricular esquerda (FEVE) < 35%, submetidos a implantação com sucesso de TRC-CDI ou CDI isoladamente (prevenção primária). Resultados: Idade média foi 63±12 anos, FEVE de 25±6%, seguimento mediano de 372 dias. Implantou-se TRC-CDI em 63 doentes (grupo A) e CDI isoladamente em 60 doentes (grupo B). No grupo A tivemos 86% de respondedores clínicos, menor prevalência de miocardiopatia isquémica(30% versus 72%), e mais doentes em classe III da NYHA antes da implantação do dispositivo(90% versus 7%) comparativamente com o grupo com CDI isoladamente. Não se identificaram diferenças relativamente à incidência de terapêuticas apropriadas (19% versus 12%) ou no tempo para a primeira terapêutica (305 dias versus 293 dias). A mortalidade total foi de 11% no grupo A e de 12% no grupo B. As curvas de Kaplan-Meier para eventos arrítmicos em doentes com TRC, não mostraram diferenças significativas (HR 3,02, IC 95% 0,82-11,09, p = NS) comparativamente com doentes sem TRC. Conclusões: Em doentes submetidos a TRC-CDI por prevenção primária, apesar da elevada taxa de respondedores, a incidência de terapêuticas apropriadas não foi diferente do obtido em doentes com CDI isoladamente.